Project Grant R41NS070387

This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research Federal Grant Program (CFDA 93.846), will enable Duke University to develop a 3D skin model system to investigate interactions between the skin microbiome and skin cell populations. The $198,782 award, effective April 10, 2025 through March 31, 2027, will fund the creation of 3D reconstructed human epidermis (RHE)...

The National Cancer Institute (NCI) awarded a $1,019,013 Cooperative Agreement under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) to the Regents of the University of California, San Francisco (UCSF) to develop a Pre-Cancer Atlas of Skin Cancer. The overarching goal is to study the early stages of skin cancer development, including melanoma and cutaneous squamous cell carcinoma, and the role of the immune system in this transition from pre-cancer to cancer. The...

This $2.757 million three-year Project Grant from the National Institutes of Health's Trans-NIH Research Support program will develop a computational framework for analyzing spatially-resolved transcriptomic datasets. The Broad Institute will integrate machine learning techniques such as representation learning, causal inference, image inpainting, and optimal transport to identify biological mechanisms underlying spatial processes in tissue contexts. Specifically, the framework will discern...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), will support research on the metabolic and epigenetic regulation of skin regulatory T cells (Tregs) at Emory University. The $597,542 award, spanning March 1, 2025 to February 28, 2030, aims to dissect the specific metabolic program governing the homeostasis of skin Tregs within their tissue microenvironment and...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $384,250 to the University of Alabama at Birmingham (UAB) to elucidate the nature of immune-stem cell interactions inadvertently targeted by immunotherapies. The project will investigate signaling between the immune checkpoint proteins PD-1 and PD-L1 as a mechanism by which immune cells and melanocyte stem cells...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $189,376 to The Regents of the University of California, San Francisco (UCSF) to investigate how skin microbiota-immune interactions drive early-life commensal tolerance. The research aims to deepen understanding of skin immune tolerance mechanisms, which could inform therapeutic targets for inflammatory skin diseases. The project will employ a...

This $178,000 Project Grant award from the National Center for Advancing Translational Sciences (NCATS), under CFDA 93.350, supports research to better understand the localization and function of the SLC24A5 gene and its role in skin pigmentation. The grantee, The Children's Hospital of Philadelphia (CHOP), will generate a panel of mouse melanocyte cell lines to investigate the subcellular localization of the NCKX5 protein encoded by SLC24A5, and assess the impact of SLC24A5 mutations on...

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $407,770 Project Grant (CFDA # 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The grant supports an exploratory study on the role of NKG2D signaling in T cell trafficking and its implications for vitiligo and melanoma. The study aims to define the underlying signaling pathways through which...

This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to develop a programmable siRNA-based therapeutic platform for gene silencing in the skin. The $249,000 award supports research at the University of Massachusetts Medical School to systematically evaluate the safety and efficacy of selective JAK1 silencing by therapeutic siRNA in mouse models...

This $1,737,000 Project Grant awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports the development of innovative single-cell genomics technologies for joint analysis of regulatory dynamics and transcriptional states. Key objectives include: Developing multiomics tools to measure rates of epigenomic changes (DNA methylation, demethylation, oxidative damage, DNA repair) and relate these to...